Dramatic Changes in Oncology Care Pathways During the COVID-19 Pandemic: The French ONCOCARE-COV Study.
COVID-19
/ epidemiology
COVID-19 Testing
/ standards
Critical Pathways
/ standards
France
/ epidemiology
Humans
Infection Control
/ standards
Mass Screening
/ standards
Medical Oncology
/ organization & administration
Neoplasms
/ diagnosis
Pandemics
/ prevention & control
Patient Care Team
/ organization & administration
SARS-CoV-2
/ isolation & purification
Telemedicine
/ standards
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
31
07
2020
accepted:
14
10
2020
pubmed:
29
10
2020
medline:
3
3
2021
entrez:
28
10
2020
Statut:
ppublish
Résumé
The coronavirus disease 2019 (COVID-19) pandemic may have affected cancer management. We aimed to evaluate changes in every oncology care pathway essential step, from screening to treatment, during the pandemic. Monthly oncological activity differences between 2019 and 2020 (screening tests, histopathological analyzes, multidisciplinary tumor board meetings (MTBMs), diagnostic announcement procedures (DAPs), and treatments were calculated in two French areas experiencing different pandemic intensity (Reims and Colmar). COVID-19 has had a dramatic impact in terms of screening (-86% to -100%), diagnosis (-39%), and surgical treatment (-30%). This global decrease in all essential oncology care pathway steps contrasted with the relative stability of chemotherapy (-9%) and radiotherapy use (-16%). Outbreak occurred earlier and with more intensity in Colmar but had a comparable impact in both areas regarding MTMBs and DAPs. The current ONCOCARE-COV study is still in progress and with a longer follow-up to analyze postlockdown situation.
Identifiants
pubmed: 33111460
doi: 10.1002/onco.13578
pmc: PMC7873337
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e338-e341Informations de copyright
© 2020 AlphaMed Press.
Références
Lancet Oncol. 2020 Aug;21(8):1035-1044
pubmed: 32702311
Ann Oncol. 2020 May;31(5):553-555
pubmed: 32201224
Pathobiology. 2021;88(1):46-55
pubmed: 32634799
Oncologist. 2020 Nov;25(11):997-1000g
pubmed: 32697887
ESMO Open. 2020 Jun;4(Suppl 2):e000828
pubmed: 32571808
J Surg Oncol. 2020 Jun 2;:
pubmed: 32488866
BMJ. 2020 Jun 12;369:m2386
pubmed: 32532710
Lancet Oncol. 2020 Jun;21(6):750-751
pubmed: 32359403
Oncologist. 2020 Jun;25(6):e936-e945
pubmed: 32243668
J Clin Pathol. 2021 Mar;74(3):187-189
pubmed: 32561524